{"id":167922,"date":"2019-09-05T11:14:05","date_gmt":"2019-09-05T11:14:05","guid":{"rendered":"http:\/\/www.georgianewsdesk.com\/news\/story\/167922\/enzymatic-wound-debridement-market-size-to-be-valued-110-billion-by-2026-grand-view-research-inc.html"},"modified":"2019-09-05T11:14:05","modified_gmt":"2019-09-05T11:14:05","slug":"enzymatic-wound-debridement-market-size-to-be-valued-110-billion-by-2026-grand-view-research-inc","status":"publish","type":"post","link":"http:\/\/www.honolulunewsnow.com\/news\/story\/167922\/enzymatic-wound-debridement-market-size-to-be-valued-110-billion-by-2026-grand-view-research-inc.html","title":{"rendered":"Enzymatic Wound Debridement Market Size to be Valued $1.10 Billion By 2026 : Grand View Research, Inc"},"content":{"rendered":"
\"Enzymatic<\/a><\/p>\n
\n
Grand View Research, Inc. – Market Research And Consulting<\/div>\n<\/div>\n<\/div>\n
According to report published by Grand View Research, The global enzymatic wound debridement market size was valued at USD 692.69 million in 2018 and is expected to grow at a CAGR of 5.8% over the forecast period.<\/div>\n

The global Enzymatic Wound Debridement Market<\/a><\/strong> size is expected to reach USD 1.10 billion by 2026, according to a new report by Grand View Research, Inc., exhibiting a 5.8% CAGR during the forecast period Introduction of technologically advanced products and rise in incidence of chronic diseases are some of the key factors aiding growth.<\/p>\n

Various initiatives are being undertaken by researchers and key players are developing technologically advanced products owing to rising demand for enzymatic wound debridement products globally, which is anticipated to boost market growth. Until now, collagenase-based enzymatic wound debridement products have been majorly used for treatment of chronic & acute wounds and papain-based products have been predominantly used for treatment of chronic wounds. Since awareness about the use of such products is increasing, several technologically advanced products are being introduced in the market. For instance, NexoBrid (NXB), previously referred to as Debriding Gel Dressing (DGD)—which is derived from pineapple Bromelain group of enzymes-was introduced in 2017. NXB is an enzymatic wound debriding drug that can be effectively used in treating deep burn wounds.<\/p>\n

The product recently received approval and market players are undertaking initiatives to launch this product under their wound care product portfolio. For instance, in May 2019, Vericel Corporation entered into a supply agreement and exclusive license with MediWound Ltd. with an aim to commercialize the product in North America. The product also received approval in European Union, the U.S., and other international markets. Therefore, such initiatives are anticipated to positively impact growth over the forecast period.<\/p>\n

\"nzymatic<\/p>\n

Request a Sample Copy of the Global Enzymatic Wound Debridement Research Report @ https:\/\/www.grandviewresearch.com\/industry-analysis\/enzymatic-wound-debridement-market\/request\/rs1<\/a><\/strong><\/p>\n

Further key findings from the report suggest:<\/span><\/strong><\/p>\n